The Relationship Between Liver Enzymes and Insulin Resistance in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease ^[*]

Abstract

Non-alcoholic fatty liver disease (NAFLD) is prevalent worldwide, especially in patients with type 2 diabetes. Liver enzymes are the main warning signs of liver injury and insulin resistance (IR) is critical to NAFLD. This study was aimed to investigate the association between liver enzymes and insulin resistance in type 2 diabetes patients with NAFLD. Data from 212 diabetes patients with NAFLD were analyzed, including 118 males and 94 females who received care from 2014 to 2015. The patients were divided into three groups by severity (mild n=87, moderate n=89, severe n=36). All patients underwent standard clinical and laboratory examinations. Liver enzymes including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and γ-glutamyl transferase (GGT) were measured, serum fasting glucose and serum fasting insulin were obtained. IR was assessed using the homeostasis model assessment insulin resistance index (HOMA-IR). Age, sex, and BMI did not significantly differ in patients (p>0.05). Compared with normal levels, elevated ALT and AST were associated with a higher HOMA-IR (p=0.0035, p=0.0096, respectively). HOMA-IR did not significantly differ (p>0.05) between patients with normal and elevated GGT. HOMA-IR increased as the levels of liver enzymes increased, and each enzyme showed a significant association with HOMA-IR (p=0.0166, p<0.0001, and p <0.0001). HOMA-IR differs between normal and elevated ALT and AST. Liver enzymes are associated with HOMA-IR in type 2 diabetes patients with NAFLD. These findings can help evaluate the degree of IR and hepatocellular steatosis in patients and prevent the progression of type 2 diabetes and NAFLD in clinical practice.

Key words

non-alcoholic fatty liver disease (NAFLD) - type 2 diabetes - insulin resistance (IR) - alanine aminotransferase (ALT) - aspartate aminotransferase (AST) - γ-glutamyl transferase (GGT)

• References

• 1 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol 2016; 7: 211-217
• 2 Andrade GC, Fujise LH, Santana Filho JE, Oliveira F, Silva RC. Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study–sample of São José do Rio Preto. Rev Assoc Méd Brasil 2015; 62: 218-226
• 3 Chon YE, Kim KJ, Jung KS, Kim SU, Park J, Kim DY, Ahn SH, Chon CY, Chung JB, Park KH, Bae JC, Han K-H. The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. Yonsei Med J 2016; 57: 885-892
• 4 Sert A, Pirgon O, Aypar E, Yilmaz H, Dündar B. Relationship between aspartate aminotransferase-to-platelet ratio index and carotid intima-media thickness in obese adolescents with non-alcoholic fatty liver disease. Clin Res Pediatr Endocrinol 2013; 5: 182-188
• 5 Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014; 59: 713-723
• 6 Makris KC, Andrianou XD, Charisiadis P, Burch JB, Seth RK, Ioannou A, Picolos M, Christophi CA, Chatterjee S. Association between exposures to brominated trihalomethanes, hepatic injury and type II diabetes mellitus. Environ Int 2016; 92–93: 486
• 7 Wainwright P, Byrne CD. Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome. Int J Mol Sci 2016; 17: 367
• 8 Ghamar-Chehreh ME, Amini M, Khedmat H, Alavian SM, Daraei F, Mohtashami R, Hadi R, Beyram B, Taheri S. Elevated alanine aminotransferase activity is not associated with dyslipidemias, but related to insulin resistance and higher disease grades in non-diabetic non-alcoholic fatty liver disease. Asian Pac J. Trop Biomed 2012; 2: 702-706
• 9 Petta S, Macaluso FS, Barcellona MR, Cammà C, Cabibi D, Marco VD, Craxì A. Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. Plos One 2012; 7: e51165
• 10 Ferreira CMA, Ferreira CJ, Baracho ML, Santana DSD, Oliveira CCDC, Lima SO, Franca AVC. Association of the nonalcoholic hepatic steatosis and its degrees with the values of liver enzymes and homeostasis model assessment-insulin resistance index. Gastroenterol Res 2015; 8: 260
• 11 Isaksen VT, Larsen MA, Goll R, Florholmen JR, Pualseen EJ. Hepatic steatosis, detected by hepatorenal index in ultrasonography, as a predictor of insulin resistance in obese subjects. BMC Obesity 2016; 3: 1-9
• 12 Kälsch J, Bechmann LP, Heider D, Best J, Manka P, Kälsch H, Sowa J, Moebus J, Slomiany U, Jöckel K, Erbel R, Gerken G, Canbay A. Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort. Sci Rep 2015; 5: 13058
• 13 Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep 2014; 2: 633-636
• 14 Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes/Metab Res Rev 2006; 22: 437-443
• 15 Lisboa QC, Costa SM, Couto CA. Current management of non-alcoholic fatty liver disease. Rev Assoc Med Brasil 2016; 62: 872-878
• 16 Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Herly M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750
• 17 Gaharwar R, Trikha S, Margekar SL, Jatav OP, Ganga PD. Study of clinical profile of patients of non alcoholic fatty liver disease and its association with metabolic syndrome. J Assoc Phys India 2015; 63: 12
• 18 Zhang R, Cheng K, Xu S, Li S, Zhou Y, Zhou S, Kong R, Li L, Li J, Feng J, Wu L, Liu T, Xia Y, Lu J, Guo C, Zhou Y. Metformin and diammonium glycyrrhizinate enteric-coated capsule versus metformin alone versus diammonium glycyrrhizinate enteric-coated capsule alone in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus. Gastroenterol Res Pract 2017; 849172
• 19 Mazzotti A, Caletti MT, Marchignoli F, Forlani G, Marchesini G. Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?. Digest Liver Dis 2017; 49: 235-240
• 20 Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatol 2010; 52: 913-924
• 21 Shujun Z, Tingting D, Jianhua Z, Huiming L, Xuan L, Junhui X, Yan Y, Xuefeng Y. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipid Health Dis 2017; 16: 15
• 22 Hossain IA, Rahman Shah MM, Rahman MK, Ali L. Gamma glutamyl transferase is an independent determinant for the association of insulin resistance with nonalcoholic fatty liver disease in Bangladeshi adults: Association of GGT and HOMA-IR with NAFLD. Diabetes Metab Syndr 2015; 10: S25-S29
• 23 Simental-Mendía LE, Rodríguez-Morán M, Gómez-Díaz R, Wacher NH, Rodríguez Hernández H, Guerrero-Romero F. Insulin resistance is associated with elevated transaminases and low aspartate aminotransferase/alanine aminotransferase ratio in young adults with normal weight. Eur J Gastroenterol Hepatol 2016; 29: 435
• 24 Jun-hui XIE, Qian LIU, YANG Yan, Liu ZL, Hu SH, Zhou XR, Yuan G, Zhang MX, Tao J, Yu XF. Correlation of liver enzymes with diabetes and pre-diabetes in middle-aged rural population in China. Huazhong University of Science and Technology and Springer-Verlag Berlin 2016; 36: 53-58
• 25 Deboer MD, Wiener RC, Barnes BH, Gurka MJ. Ethnic differences in the link between insulin resistance and elevated ALT. Pediatrics 2013; 132: e718-e726
• 26 Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty live disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab 1900; 19: 597-601
• 27 Gómezsámano MA, Cuevasramos D, Mehta R, Braufigueroa H, Mezaarana CE, Guliasherrero A. Association of Alanine Aminotransferase Levels (ALT) with the Hepatic Insulin Resistance Index (HIRI): A cross-sectional study. BMC Endocr Disord 2012; 12: 16
• 28 Velu VK, Jyothirmayi B, Kumar JS. Insulin resistance and alanine amino transaminase (ALT) levels in first degree relatives o type 2 diabetes mellitus. Diabetes Metab Syndr 2011; 5: 143
• 29 Wei D, Chen T, Gao Y, Tian H. Serum gamma-glutamyl transferase and ferritin are related to insulin resistance: A population-based study. Clin Lab 2015; 61: 1157-1161
• 30 Bradley R, Fitzpatrick AL, Jenny NS, Lee DH, Jacobs Jr DR. Associations between total serum GGT activity and metabolic risk: MESA. Biomark Med 2013; 7: 709
• 31 Mills EP, Brown KPD, Smith JD, Vang PW, Trotta K. Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A review of efficacy and safety. Therap Adv Endocrinol Metab 2017; 9: 15-28